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AbsTrACT
Aims Understanding the molecular mechanisms of 
underlying disease has led to a movement away from the 
one-drug-fits-all paradigm towards treatment tailored 
to the genetic profile of the patient. The Biocartis Idylla 
platform is a novel fully automated, real-time PCR–
based in vitro diagnostic system. The Idylla NRAS-BRAF 
mutation test has been developed for the qualitative 
detection of mutations in NRAS and BRAF oncogenes, 
facilitating genetic profiling of patients with cancer. 
The aim of this study was to carry out a formal clinical 
performance evaluation.
Methods Two-hundred and forty-two formalin-
fixed paraffin-embedded (FFPE) human malignant 
colorectal cancer (CRC) tissue samples were identified 
in departmental archives and tested with both the Idylla 
NRAS-BRAF mutation test and the Agena Bioscience 
MassARRAY test.
results The overall concordance between the Idylla 
NRAS-BRAF mutation test and the MassARRAY 
comparator reference test result was 241/242 (99.59%, 
lower bound of one-sided 95% CI=98.1%) for 
NRAS and 242/242 (lower bound of 95% one-sided 
95% CI=98.89%) for BRAF. The Idylla NRAS-BRAF test 
detected one NRAS mutation that had not been reported 
by the MassARRAY comparator reference test. Reanalysis 
of this sample by droplet digital PCR confirmed that the 
mutation was present, but at an allelic frequency below 
the stated sensitivity level of the MassARRAY system.
Conclusion These results confirm that the Idylla NRAS-
BRAF mutation test has high concordance with a widely 
used NRAS-BRAF test, and is therefore suitable for use 
as an in vitro diagnostic device for this application.
InTrOduCTIOn
The epidermal growth factor receptor (EGFR) and 
its downstream signalling pathways are involved in 
the development and progression of several human 
tumours including colorectal cancer (CRC).1–3 Acti-
vated signalling pathways including the RAS-RAF-
BRAF-MAPK and the phosphatidylinositol 
3-kinase (PI3K)-Akt pathways are key drivers of 
tumour growth and progression.4 5 Patients with 
CRC can be successfully treated with anti-EGFR 
monoclonal antibody therapies, such as panitu-
mumab or cetuximab, which work by disrupting 
EGFR signals6–10—provided the tumours do not 
have mutations in EGFR signalling pathways.11–14 
Testing patients for specific mutations that are 
linked to lack of response to EGFR blockade prior 
to commencing therapy ensures they receive the 
most appropriate treatment, and that treatment 
benefits, adverse effects and costs will be optimised.
Reduced anti-EGFR treatment efficacy was 
initially thought to be the result of mutations within 
KRAS exon 2 (codons 12 and 13). Therefore, KRAS 
genotyping was routinely used to stratify patients 
with CRC into those likely to respond to anti-
EGFR therapy and those unlikely to respond. 
Further mutations causing resistance to anti-EGFR 
therapy were subsequently discovered through two 
large clinical studies (PRIME and CRYSTAL) which 
showed that 14%–17% wild-type (WT) KRAS exon 
2 individuals actually responded poorly to anti-
EGFR therapy.9 15 It is now known that resistance 
to therapy has a range of genetic causes: mutations 
in KRAS (exons 2, 3 and 4) and NRAS (exons 2, 
3 and 4) are found in 40%–45% and 5%–10% of 
patients, respectively.5 16 17 BRAF V600E mutation 
is detected in 4%–18% of CRC cases and is prog-
nostic of outcomes, but, in contrast to KRAS which 
is predictive of response is not used to guide anti-
EGFR treatment.16–19
The Idylla System (Biocartis, Mechelen, Belgium) 
is a fully automated, real-time PCR-based molecular 
diagnostics system.20–26 The Idylla NRAS-BRAF 
mutation test is a novel in vitro diagnostic medical 
device (IVD) for the qualitative detection of muta-
tions in codons 12, 13, 59, 61, 117 and 146 of the 
NRAS oncogene and codon 600 in the BRAF onco-
gene in formalin-fixed paraffin-embedded (FFPE) 
human malignant CRC tissue. This non-randomised 
study, was a clinical performance evaluation of the 
Idylla NRAS-BRAF mutation test with retrospec-
tively collected samples and prospectively planned 
data generation.
MATerIAls And MeThOds
The Idylla platform
The Idylla molecular diagnostic platform is a fully 
automated, allele-specific real-time PCR-based 
molecular diagnostic system.20 It combines sample 
preparation with PCR thermocycling to detect 
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molecular targets from a variety of solid and liquid samples 
including FFPE slices. Briefly, FFPE tissue sections are placed 
directly into the Idylla system cartridge, with no preprocessing. 
The cartridge is then inserted into the Idylla platform, where 
high-intensity focused ultrasound (HiFu) technology, buffers, 
reagents and heat induces deparaffinisation, tissue disruption, 
cell lysis and subsequent release of nucleic acid. Allele-specific 
primers and fluorescent probes then perform real-time PCR 
amplification and mutation detection. All required consum-
ables are provided in the cartridge, and the Idylla Console and 
instruments are CE marked.
The Idylla nrAs-brAF mutation test
The Idylla NRAS-BRAF mutation test uses allele-specific multi-
plex PCR reactions to amplify 23 mutations in codons 12, 13, 
59, 61, 117, 146 of the NRAS oncogene and codon 600 of the 
BRAF oncogene. A set of parameters describing the generated 
PCR curves are determined by the Idylla software, for example, 
ΔCq value (calculated as the difference between the quantifica-
tion cycle value (Cq) of the gene control signal and the Cq of the 
mutant signal). A sample is classified as mutation positive if the 
parameters of the PCR curve generated are within the validated 
range. Otherwise the sample is reported as being mutation nega-
tive, that is, WT. Table 1 lists the mutations detected by the test.
The results obtained from the Idylla NRAS-BRAF mutation 
test during this study were not used for clinical or diagnostic 
purposes and were not made available to patients or their 
clinicians.
The comparator test
The NRAS and BRAF mutation status for each FFPE tissue sample 
was assessed using the MassARRAY System (Agena Bioscience). 
Existing test results were used if the comparator test had been 
performed within 2 years of the start of this study and no further 
slides or slices had been taken from the source FFPE block. H&E 
slides were taken at the start and end of block slicing to confirm 
sample homogeneity. If the sample block had been cut since 
the initial comparator test analysis, newly prepared alternating 
slides/slices were taken to rerun the comparator test. To reduce 
the risk of bias, different operators performed testing on the 
MassARRAY System and the Idylla NRAS-BRAF mutation test.
The Agena MassArrAY mutation test
The Agena MassARRAY mutation test used in this study is a 
Laboratory Developed Test which is within the scope of the ISO 
15189 accreditation held by NewGene Ltd, and is routinely used 
clinically. Samples with known mutation profiles, as used during 
clinical validation of the assay for ISO 15189 accreditation, were 
Table 1 NRAS and BRAF mutations detected by the Idylla NRAS-BRAF mutation test
Gene exon Codon Mutation Protein nucleotide change Genetic call
NRAS 2 12 G12D p.(Gly12Asp) c.35G>A G12D
G12C p.(Gly12Cys) c.34G>T G12C
G12S p.(Gly12Ser) c.34G>A G12S
G12A p.(Gly12Ala) c.35G>C G12A/V
G12V p.(Gly12Val) c.35G>T
13 G13D p.(Gly13Asp) c.38G>A G13D
G13R p.(Gly12Arg) c.37G>C G12R/V
G12V p.(Gly13Va) c.38G>T
3 59 A59T p.(Ala59Thr) c.175G>A A59T
61 Q61K p.(Gln61Lys) c.181A>G Q61K
Q61R p.(Gln61Arg) c.182A>G Q61R
Q61L p.(Gln61Leu) c.182A>T Q61L
Q61H p.(Gln61His) c.183A>T Q61H
Q61H p.(Gln61His) c.183A>T
4 117 K117N p.(Lys117Asn) c.351G>C K11N
K117N p.(Lys117Asn) c.351G>T
A146T p.(Ala146Thr) c.426G>A A146T/V
A146V p.(Ala146Val) c.437C>T
BRAF 15 600 V600E p.(Val600Glu) c.1799T>A V600E/D
V600E p.(Val600Glu) c.1799_1800delinsAA
V600D p.(Val600Asp) c.1799_1800delinsAC
600 V600K p.(Val600Lys) c.1798_1799delinsAA V600K/R
V600R p.(Val600Arg) c.1798_1799delinsAA
box 1 sample selection criteria
Formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) 
samples were included if they were:
 ► Obtained from male or female patients≥18 years of age
 ► Approved for investigational purposes according to the 
applicable laws
 ► Histologically confirmed to be primary or metastatic 
malignant CRC
 ► Fixed in formalin for a maximum time of 48 hours
 ► Less than 10 years old and had been stored at ambient 
conditions
 ► Stored at room temperature for not more than 60 days prior 
to Idylla testing
CRC samples were excluded if:
 ► The patient declined to provide their sample to third parties 
for research purposes
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used as positive controls. ‘No template’ reactions, prepared with 
deionised H2O in place of template DNA were used as controls 
for non-specific amplification.
MassARRAY utilises the primer extension analytical method 
to determine the presence or absence of single nucleotide 
polymorphisms (SNPs) which cause specific mutations in the 
protein encoded by a gene. First, target region-specific PCR 
with short amplicons is used to amplify the DNA encoding the 
target sequence. These PCR products are then probed for the 
presence of the mutation of interest using an oligonucleotide 
which is complementary to the region immediately adjacent 
to the SNP location. This is then extended by only one base, 
using 2',3' dideoxynucleotides (ddNTPs); the ddNTP which 
terminates the oligonucleotide chain corresponds to the base 
code at the SNP location. A matrix-assisted laser desorption/
ionization time-of-flight (MALDI-ToF) mass spectrometry 
system is then used to differentiate between oligonucleotide 
species on the basis of their differing masses, identifying the 
various SNP bases present at that location and also quantifying 
the relative allelic frequency of the mutant sequence versus 
the WT.
study size estimation
The number of samples required for a diagnostic agreement 
study with 80% power and expected agreement rate of 95% is 
188. To allow for invalid runs and samples, the target number of 
FFPE tumour tissue blocks to be tested was set at 250. At least 
Figure 1 Formalin-fixed paraffin-embedded (FFPE) sample preparation algorithm prior to Idylla NRAS-BRAF mutation test. Histologically confirmed, 
retrospectively collected FFPE colorectal cancer tissue samples were identified and tissue sections 5 or 10 µm thick were sampled as close as possible 
(within the same FFPE block) to the sections used for reference testing. Prior to analysis, the tumour content and area were determined on a H&E slide 
by a consultant histopathologist at both sites. If required, macrodissections were performed to ensure tumour nuclei content of more than 10% in the 
sample for analysis. The volume of material was specified to ensure that there was sufficient for the assay while not overloading the device.
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30 valid FFPE samples with known NRAS mutations, at least 30 
samples with known BRAF mutations, and up to 190 samples 
with WT KRAS were planned to be included.
Tissue selection criteria and process
The inclusion criteria for samples can be found in box 1. Samples 
were obtained from two centres: The Royal Victoria Infirmary, 
Newcastle upon Tyne Hospitals NHS Foundation Trust (UK; 
n=113), and the Institute of Pathology, Aarhus University 
Hospital (Denmark; n=156). All available samples were entered 
into the study. Figure 1 shows how FFPE tissue samples were 
prepared for use in the Idylla NRAS-BRAF mutation test.
The protocol specified that samples should have at least 10% 
of their content identified as tumorous cells because the clinical 
importance of results (concordant or discrepant) from samples 
with very low proportions of tumorous cells could be debatable.
diagnostic performance measurements
baseline testing
No discrepancies were observed between the original results 
and the repeat results when retesting with the MassARRAY was 
performed on specimens that had originally been tested with 
other devices.
Percentage agreement
As it is not feasible to set-up a study with large numbers of each 
individual mutant, the performance of the Idylla NRAS-BRAF 
mutation test was scored based on total agreement. Overall 
agreement (% total agreement), and negative and positive agree-
ments were determined together with their 95% one-sided CIs. 
Overall agreement was defined as the proportion of concor-
dant results in all results. Positive agreement was defined as the 
proportion of concordant results in positive Idylla results. Nega-
tive agreement was defined as the proportion of concordant 
results in negative Idylla results.
discordant by design results
The Idylla NRAS-BRAF panel detects 18 NRAS mutations and 
5 BRAF mutations (table 1), while the MassARRAY NRAS-
BRAF panel detects 25 NRAS mutations and provides a BRAF 
V600E result as a generic call rather than distinguishing between 
V600E/D or V600K/R. The seven additional NRAS mutations 
detected by the MassARRAY but not by the Idylla NRAS-BRAF 
Figure 2 Process of enrolling samples into the study.
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mutation test panel include G12R, G13C, G13S, G13A, Q61P 
and Q61E. Samples that were anticipated to produce discor-
dant results because of design differences in the Idylla and 
MassARRAY systems were classed as ‘discordant by design’ and 
were excluded from analysis.
Investigation of discordant results
Discordant results were further investigated by using 
droplet digital PCR as a second comparator test to evaluate the 
accuracy of the Idylla result. Droplet digital PCR was performed 
on a QX100TM system (Bio-Rad Laboratories, Hercules, Cali-
fornia, USA) according to the instructions of the manufacturer.
resulTs
samples included
Two hundred and sixty-nine FFPE CRC samples were initially 
identified for the study (figure 2), and 242 samples included in 
the performance evaluation. Twenty-seven FFPE samples were 
excluded because they failed to meet the inclusion criteria. The 
most common reason for exclusion was insufficient sample 
quantity (n=11). One FFPE sample was excluded because it 
was classified as discordant by design. Seven samples resulted 
in a failed run, three of which were due to insufficient sample 
(assay failure) and four of which were due to instrument errors 
(system failure). This equates to assay and system failure rates 
of 1.24% and 1.74%, respectively. All invalid and error runs 
were successfully repeated and included in the agreement anal-
ysis as specified in the protocol. Samples included in the study 
ranged from blocks of tumour from resections (198) to small 
diagnostic core biopsies (44). Macrodissection was required in 
126 samples. The proportions of tumour ranged from 20% to 
60% in sections without macrodissection, and from 10% to 75% 
in sections requiring macrodissection.
The photomicrographs in figure 3 are from samples which 
show extensive mucinosis (A) extensive necrosis (B) and a small 
core biopsy (C). The Idylla NRAS-BRAF mutation test was able 
to detect mutations in all such samples.
baseline demographic and clinical characteristics
The final study population demographics and clinical characteris-
tics are presented in table 2. Gender representation was balanced 
between males and females (54% and 46%, respectively). The 
mean age at tumour collection was 67.6 years (range: 24–96 
years). The majority of samples (91%) were of primary tumour 
tissues originating from the colon. The remaining samples were 
from metastatic deposits originated in the liver (3%) or another 
(6%) location. All samples were histologically confirmed as 
malignant CRC; 85% were KRAS WT, 15% had an NRAS muta-
tion and 21% had a BRAF mutation.
Clinical performance of the Idylla nrAs-brAF mutation test
The NRAS and BRAF mutational status of 242 retrospectively 
collected FFPE CRC samples was tested with the NRAS-BRAF 
mutation test. Results were compared with assessments made by 
the MassARRAY comparator reference test. Of the 242 FFPE 
samples analysed by the NRAS-BRAF Mutation Test, 36 tested 
positive for a mutation in NRAS, and in 205 cases, no NRAS 
mutation was found (table 3). As presented in table 4, results 
obtained by the NRAS-BRAF mutation test for NRAS testing were 
in agreement with the results obtained from the MassARRAY 
comparator reference test for 241 of 242 samples, resulting in 
an overall concordance of 99.59%, (lower bound of one-sided 
95% CI=98.17%) with positive agreement of 100% (lower 
bound of one-sided 95% CI=93.0%) and a negative agreement 
of 99.51% (lower bound of one-sided 95% CI=97.85%).
Of the 242 FFPE samples, 52 tested positive for BRAF V600E/D 
mutation; no mutation was found in 190 cases. Results obtained 
by the NRAS-BRAF mutation test for BRAF testing were fully 
in agreement with the results obtained from the MassARRAY 
comparator reference test resulting in an overall concordance 
of 100% (lower bound of one-sided 95% CI=98.89%) (table 4).
discordant result
In one case, a G12D NRAS mutation was detected by the NRAS-
BRAF mutation test but not by the MassARRAY comparator 
reference test (tables 3 and 4). The NRAS G12D result was 
confirmed to be a true positive by ddPCR analysis with an allelic 
frequency of around 0.5%, which is well below the 5% limit of 
detection of the MassARRAY system (table 5).
Figure 3 Photomicrograph of tumour samples used for performance 
evaluation study. (A) sample with extensive mucinosis; (B) sample with 
extensive necrosis; (C) sample from small core biopsy of metastatic 
colon adenocarcinoma in the liver. The core was divided lengthways 
before embedding and the total section area was 25 mm2, the minimum 
specified in the protocol. The sample tested positive in both platforms 
without macrodissection and included solid adenocarcinoma (top left) 
normal liver (top right) and mucinous stroma (lower core).
Table 2 Baseline demographic and clinical characteristics for 
participants with valid test results
Gender
  Male 131 (54%)
  Female 111 (46%)
Mean age (years) at tumour tissue collection date 67.6 (SD 10.96)
Histologically confirmed malignant 
colorectal cancer
242 (100%)
Tissue location
  Primary 220 (91%)
  Metastatic (liver) 7 (3%)
  Metastatic (other) 15 (6%)
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dIsCussIOn
The importance of testing for NRAS and BRAF mutations in 
tumours from patients with CRC is reflected in recent clinical 
practice recommendations of the American Society of Clinical 
Oncology27 and the European Society for Medical Oncology.28 
NRAS mutations in colorectal tumours are associated with poor 
response to anti-EGFR therapy while BRAF mutations are asso-
ciated with reduced survival.29 Evidence-based guidelines there-
fore recommend NRAS (predictive) testing to guide treatment 
decisions and BRAF (prognostic) testing to provide information 
on outcomes.27 28
The performance of the Idylla platform has been previously 
reported in various validation studies.23 24 30–33 In the present 
study, results from the Idylla NRAS-BRAF mutation test, which 
can detect 18 NRAS and five BRAF clinically relevant and action-
able mutation targets, were compared with results obtained from 
NRAS and BRAF mutation testing by the MassARRAY.
There was greater than 99.5% concordance between the Idylla 
platform results and MassArray findings for NRAS and BRAF 
testing. Droplet digital PCR testing of the one discordant result 
confirmed the Idylla identification. One plausible explanation 
for this finding is that Idylla may have a lower limit of detection 
than the MassARRAY reference test; other possible explanations 
include test error and sample error.
Both the Idylla platform and MassARRAY methods were 
highly sensitive, and mutations could be reliably detected in 
small core biopsies and in samples with extensive mucinosis or 
necrosis.
As with other products based on similar technologies that 
identify specific mutations, mutations that are not intended to 
be detected will not be detected. However, these technologies in 
general, and the Idylla system, in particular, have the advantage 
of being able to readily update their assays to include mutations 
newly recognised as being clinically important, although revali-
dation for CE marking may be required.
In conclusion, the Idylla NRAS-BRAF mutation test is a 
fully automated and integrated real-time PCR-based test with 
high sensitivity and rapid turnaround time, providing results 
that are readily interpreted by clinicians. The Idylla platform 
proved straightforward to use with or without macrodissection. 
The method of handling the FFPE sections is distinct to Idylla 
and contrasts with the more usual method of placing the FFPE 
sections into a container. FFPE samples are loaded directly into 
single use cartridges with minimal sample preparation: histolog-
ical sections (curls) for analysis are easily ‘sandwiched’ between 
the filter papers in the cassette. Potential drawbacks include the 
limited throughput (four samples per unit per day) and inability 
to retrieve samples and rescue an analysis if the system malfunc-
tions mid-run. The Idylla platform would ideally be set up in 
a clean room close to where the paraffin sections are being 
prepared in a pathology laboratory and employed in clinical 
settings where the time saved by analysis on demand (compared 
with routine batch processing) would provide clinical and/or 
efficiency benefits. The Agena MassARRAY system can test from 
1 to 384 samples on a chip (depending on the panels of tests and 
number of wells) and can process around 120 colorectal muta-
tion tests per day.
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